...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>EBioMedicine >Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia
【24h】

Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia

机译：亚洲初发非肌肉侵袭性膀胱癌的新型复发风险分层的开发和验证

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Some risk classifications to determine prognosis of patients with non-muscle invasive bladder cancer (NMIBC) have disadvantages in the clinical setting. We investigated whether the EORTC (European Organization for Research and Treatment of Cancer) risk stratification is useful to predict recurrence and progression in Japanese patients with NMIBC. In addition, we developed and validated a novel, and simple risk classification of recurrence. Methods: The analysis was based on 1085 patients with NMIBC at six hospitals. Excluding recurrent cases, we included 856 patients with initial NMIBC for the analysis. The Kaplan-Meier method with the log-rank test were used to calculate recurrence-free survival (RFS) rate and progression-free survival (PFS) rate according to the EORTC risk classifications. We developed a novel risk classification system for recurrence in NMIBC patients using the independent recurrence prognostic factors based on Cox proportional hazards regression analysis. External validation was done on an external data set of 641 patients from Kyorin University Hospital. Findings: There were no significant differences in RFS and PFS rates between the groups according to EORTC risk classification. We constructed a novel risk model predicting recurrence that classified patients into three groups using four independent prognostic factors to predict tumour recurrence based on Cox proportional hazards regression analysis. According to the novel recurrence risk classification, there was a significant difference in 5-year RFS rate between the low (68.4%), intermediate (45.8%) and high (33.7%) risk groups (P<0.001). Interpretation: As the EORTC risk group stratification may not be applicable to Asian patients with NMIBC, our novel classification model can be a simple and useful prognostic tool to stratify recurrence risk in patients with NMIBC. Funding: None.
机译：背景：一些确定非肌肉浸润性膀胱癌（NMIBC）患者预后的风险分类在临床环境中不利。我们调查了EORTC（欧洲癌症研究和治疗组织）风险分层是否可用于预测日本NMIBC患者的复发和进展。此外，我们开发并验证了新颖，简单的复发风险分类。方法：该分析基于六家医院的1085例NMIBC患者。除复发病例外，我们纳入了856例初始NMIBC患者进行分析。根据EORTC风险分类，采用带有对数秩检验的Kaplan-Meier方法计算无复发生存率（RFS）和无进展生存率（PFS）。我们使用基于Cox比例风险回归分析的独立复发预后因素，开发了NMIBC患者复发的新型风险分类系统。外部验证是根据Kyorin大学医院的641例患者的外部数据进行的。结果：根据EORTC风险分类，两组之间的RFS和PFS率无显着差异。我们构建了一个新的预测复发的风险模型，该模型使用四个独立的预后因素将患者分为三组，以基于Cox比例风险回归分析预测肿瘤的复发。根据新的复发风险分类，低风险组（68.4％），中风险组（45.8％）和高风险组（33.7％）的5年RFS率存在显着差异（P <0.001）。解释：由于EORTC风险组分层可能不适用于亚洲NMIBC患者，因此我们新颖的分类模型可以作为对NMIBC患者复发风险进行分层的简单有效的预后工具。资金：无。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号